TICKERNERD
Menu
CORCORHealthcare · Medical Distribution

COR Stock Forecast: Cencora, Inc. Price Predictions for 2026-2027

Last close, 16 Oct 2026
$341
−0.14% on the day

The 14 Wall Street analysts covering Cencora, Inc. hold a median 12-month price target of $367 — +7.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 15 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$65.2B
Ticker Nerd rank
74 / 100
Median analyst target
$367
Analysts covering
14
Revenue$84.8B+5.1% y/y
Operating income$1.2B
Net income$776.7M
Free cash flow$2.4B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.3%
1M
+7.0%
YTD
+1.5%
1Y
+7.5%
From 52W high
−8.5%
From 52W low
+35.5%
$252
$373
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cencora, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Oct 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
88
Growth
76
Momentum
72
Quality
70
Revisions
62
Issuance
55
Accruals
43
Size
4

Volatility (99): The share price has been relatively steady.

Accruals (43): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400$450Jan 26Apr 26Jul 26Oct 26CORHigh $430Median $367Low $330

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
10 Buy4 Hold0 Sell
Low $330Median $367High $430

The green dot is the last close — the median target sits +7.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Oct 2026Leerink PartnersMaintainsOutperform$380 → $388
8 Sept 2026RBC CapitalReiteratesSector Perform—
8 Sept 2026RBC CapitalReiteratesSector Perform$330
19 Aug 2026RBC CapitalInitiatesSector Perform$330
19 Aug 2026RBC CapitalInitiatesSector Perform—
11 Aug 2026Wells FargoMaintainsOverweight$331 → $395
11 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026JP MorganMaintainsOverweight$382 → $390
7 Aug 2026Morgan StanleyMaintainsOverweight—
7 Aug 2026Morgan StanleyMaintainsOverweight$342 → $346
6 Aug 2026Evercore ISI GroupMaintainsOutperform$330 → $350
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026UBSMaintainsBuy—
6 Aug 2026UBSMaintainsBuy$412 → $430
24 June 2026B of A SecuritiesMaintainsNeutral$280 → $285
24 June 2026B of A SecuritiesMaintainsNeutral—
10 June 2026BarclaysMaintainsOverweight—
11 May 2026Wells FargoMaintainsOverweight—
7 May 2026BairdMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 16 Oct 2026, Cencora, Inc. returned +7.5% against +16.8% for the S&P 500, dividends included.

COR vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26CORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
10
Analysts cutting
0
Fundamentals

Cencora, Inc. (COR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.5×

Cheaper than 31% of US stocks

Price / sales
0.2×

Cheaper than 92% of US stocks

Price / book
21.4×

Cheaper than 4% of US stocks

EV / EBITDA
13.9×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
5.1%

Higher than 39% of US stocks

Earnings growth (YoY)
11.1%

Higher than 49% of US stocks

Gross margin
4.3%

Higher than 6% of US stocks

Operating margin
1.4%

Higher than 48% of US stocks

Net margin
0.8%

Higher than 49% of US stocks

Returns & dividend
Return on equity
96.9%

Higher than 96% of US stocks

Return on assets
3.6%

Higher than 69% of US stocks

Dividend yield
0.7%

Higher than 68% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cencora, Inc. (COR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cencora, Inc. has a market value of $65.2B and an enterprise value of $77.0B.

  • Revenue in the twelve months to 30 June 2026: $332.8B. The latest quarter grew 5.1% year on year.

  • Net income over the same four quarters: $2.6B, a 0.8% net margin.

  • Diluted earnings per share, trailing twelve months: $13.46.

  • Free cash flow in the twelve months to 30 June 2026: $4.1B, after $760.8M of capital spending.

  • Cencora, Inc. spent $1.0B on share buybacks and $468.1M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 190.8M.

  • Trailing P/E: 24.5×; forward P/E: 17.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.70%, paying out 17% of earnings.

  • Cencora, Inc. employs 47,000 people — $7.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Oct 2026

Data provided by Twelve Data

Peers

COR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
CORCencora, Inc.$65.2B
74
CAHCardinal Health, Inc.$58.7B
96
MCKMcKesson Corp.$116.9B
90
HSICHenry Schein, Inc.$10.0B
83
BSXBoston Scientific Corp.*$65.4B
55
NTRANatera, Inc.*$55.9B
82
CIThe Cigna Group*$79.0B
76

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cencora, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COR news & analysis

AI Disruption May Benefit Cencora More Than Hims & Hers

Seeking Alpha · 14 Oct 2026positive

Seeking Alpha says Cencora could benefit from AI-driven prescription-volume growth as regulatory pilots expand automated prescribing. It also cites 17% year-over-year adjusted operating income growth against 4.9% sales growth and discusses valuation and a potential re-rating.

Why it matters — The article highlights how automated prescribing and AI-enabled operational efficiencies may affect Cencora’s business and recent operating results.

Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow

Seeking Alpha · 6 Oct 2026positive

Seeking Alpha reaffirmed its prior buy rating on Cencora, citing supportive business and macro fundamentals amid growing healthcare supply-chain needs. The article highlights the company's investment-grade rating, positive operating cash flow, dividend safety, and improved operating margin.

Why it matters — COR watchers would care because the reaffirmed buy rating and highlighted financial strengths point to continued stability and growth potential in the healthcare supply-chain space despite some market underperformance.

Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

Business Wire · 2 Oct 2026neutral

Cencora announced it will release its Fourth Quarter Fiscal 2026 results on Wednesday, November 4, 2026, prior to market open, and will host a conference call at 8:30 a.m. ET that day. CEO Robert P. Mauch and EVP & Chief Financial Officer Eva C. Boratto are scheduled to participate in the call.

Why it matters — The announcement provides COR watchers with the scheduled date and details for the company's fiscal fourth-quarter earnings report and conference call.

Cencora Elects Robert E. Sanchez to Its Board of Directors

Business Wire · 25 Sept 2026neutral

Cencora, Inc. announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executive Chair of Ryder System, Inc. and previously served as its Chair and CEO until his retirement in March 2026.

Why it matters — The appointment adds an experienced executive with decades of leadership at Ryder System to Cencora's board, potentially bringing fresh independent oversight and governance perspective to the company.

Here's Why Cencora (COR) is a Strong Growth Stock

Zacks Investment Research · 23 Sept 2026positive

Zacks Investment Research highlights Cencora (COR) as a strong growth stock using its Zacks Style Scores framework, which helps identify market-beating stocks for investors' portfolios.

Why it matters — A COR watcher would care because the piece signals the stock is viewed favourably by a recognised research ranking system for growth characteristics.

FAQ

Frequently asked questions about COR stock

What is the COR stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Cencora, Inc. have a median 12-month price target of $367, with estimates ranging from $330 to $430. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COR stock a buy right now?

Of the 14 analysts covering Cencora, Inc., 10 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cencora, Inc. 74 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COR?

As at 15 Oct 2026, Cencora, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will COR stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +7.5% from the last close, and Ticker Nerd's factor model ranks Cencora, Inc. 74 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COR stock forecast for 2030?

No analyst covering Cencora, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $330 to $430 over the next 12 months.

How has COR stock performed over the past year?

Cencora, Inc. returned +7.5% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cencora, Inc. do?

Cencora Inc. is a global pharmaceutical solutions company focused on the sourcing, distribution, and commercialization of medicines and healthcare products.

What is the latest news on COR?

The most recent item we track (Seeking Alpha, 14 Oct 2026): "AI Disruption May Benefit Cencora More Than Hims & Hers". Seeking Alpha says Cencora could benefit from AI-driven prescription-volume growth as regulatory pilots expand automated prescribing. It also cites 17% year-over-year adjusted operating income growth against 4.9% sales growth and discusses valuation and a potential re-rating.

Company

About Cencora, Inc.

Cencora Inc. is a global pharmaceutical solutions company focused on the sourcing, distribution, and commercialization of medicines and healthcare products. The company supports manufacturers, pharmacies, hospitals, health systems, and other care providers through wholesale distribution, specialty pharmacy services, patient access support, and supply chain solutions. Its business also includes international pharmaceutical wholesale, global commercialization services, and logistics for temperature-sensitive therapies. Cencora serves both human and animal health markets, helping improve product availability and operational efficiency across the healthcare ecosystem. Headquartered in Conshohocken, Pennsylvania, Cencora operates as a key intermediary in the pharmaceutical supply chain, connecting drug makers with the organizations that deliver care.

CEO Dr. Robert P. Mauch Ph.D., PharmD · 47,000 employees · United States · https://www.cencora.com